Literature DB >> 22517604

Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?

Charlotte I S Barker1, Joseph F Standing, Mark A Turner, James C McElnay, Mike Sharland.   

Abstract

PURPOSE OF REVIEW: Antibiotics are prescribed more frequently to children than any other class of medication. Analysis of the evidence behind antimicrobial dosing regimes is imperative to improve clinical outcomes, minimize antimicrobial resistance development, and to identify priority research areas for the future. This review aims to promote debate amongst paediatricians, pharmacologists, and pharmacists about how to improve antimicrobial prescribing by considering methods to develop and disseminate optimal dosage information. RECENT
FINDINGS: There has been increasing use of population analyses to understand pharmacokinetic/pharmacodynamic (PK/PD) parameters in children. Nonlinear mixed effects modelling is widely accepted to be the method of choice for analyses of PK/PD data. However, communicating the quality of PK/PD studies is an equally important factor to allow clinicians to gauge the robustness of the evidence. The possibility of grading PK/PD studies is discussed, along with using systematic reviews and PK/PD meta-analysis for generating high-quality evidence.Many doses in existing formularies (including the British National Formulary for Children) are based on outdated evidence. The need to update formularies to account for new evidence, population changes (e.g. obesity), and changing patterns of resistance requires a more systematic evaluation of antimicrobial PK/PD relationships in children. The possibility of e-formularies with links directly to the evidence should be considered and regulators must also play a role in supporting the re-evaluation of off-patent dosing guidelines.
SUMMARY: Advancing our understanding of the evidence behind paediatric antimicrobial therapeutic regimens is essential to improve both clinical outcomes and patient safety. Using a combination of international collaboration, electronic communication, and PK/PD modelling techniques, we can now define the gaps in our knowledge base and develop the techniques to answer them.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517604     DOI: 10.1097/QCO.0b013e328353105c

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  10 in total

1.  A Comprehensive List of Items to be Included on a Pediatric Drug Monograph.

Authors:  Lauren E Kelly; Shinya Ito; David Woods; Anthony J Nunn; Carol Taketomo; Matthijs de Hoog; Martin Offringa
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

2.  Information provision for antibacterial dosing in the obese patient: a sizeable absence?

Authors:  Sara Elizabeth Boyd; Esmita Charani; Tracy Lyons; Gary Frost; Alison Helen Holmes
Journal:  J Antimicrob Chemother       Date:  2016-08-18       Impact factor: 5.790

Review 3.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

4.  Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design.

Authors:  Karin Kipper; Charlotte I S Barker; Joseph F Standing; Mike Sharland; Atholl Johnston
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.

Authors:  Colin R Garner; Kevin B Park; Neil S French; Caroline Earnshaw; Alessandro Schipani; Andrew M Selby; Lindsay Byrne; Sarah Siner; Francis P Crawley; Wouter H J Vaes; Esther van Duijn; Rianne deLigt; Heili Varendi; Jane Lass; Grzegorz Grynkiewicz; Wioletta Maruszak; Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

6.  Oral penicillin prescribing for children in the UK: a comparison with BNF for Children age-band recommendations.

Authors:  Sonia Saxena; Zareen Ismael; Macey L Murray; Charlotte Barker; Ian C K Wong; Mike Sharland; Paul F Long
Journal:  Br J Gen Pract       Date:  2014-04       Impact factor: 5.386

7.  Antibiotic Exposure in Early Life Increases Risk of Childhood Obesity: A Systematic Review and Meta-Analysis.

Authors:  Xiaoqing Shao; Xiaolian Ding; Bin Wang; Ling Li; Xiaofei An; Qiuming Yao; Ronghua Song; Jin-An Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-20       Impact factor: 5.555

Review 8.  Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 5.577

9.  A comparison of five paediatric dosing guidelines for antibiotics.

Authors:  Shrey Mathur; Charlotte Jackson; Heather Urus; Isabelle Ziarko; Matt Goodbun; Yingfen Hsia; Sally Ellis; Mike Sharland
Journal:  Bull World Health Organ       Date:  2020-04-28       Impact factor: 9.408

Review 10.  Understanding and applying pharmacometric modelling and simulation in clinical practice and research.

Authors:  Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.